dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Martín, María C. |
dc.contributor.author | Jurado, Aurora |
dc.contributor.author | Abad Molina, Cristina |
dc.contributor.author | Orduña, Antonio |
dc.contributor.author | Yarce, Oscar |
dc.contributor.author | Navas, Ana M. |
dc.contributor.author | Hernández González, Manuel |
dc.contributor.author | Perurena Prieto, Janire |
dc.date.accessioned | 2022-01-13T17:53:51Z |
dc.date.available | 2022-01-13T17:53:51Z |
dc.date.issued | 2021-05-20 |
dc.identifier.citation | Martín MC, Jurado A, Abad-Molina C, Orduña A, Yarce O, Navas AM, et al. The age again in the eye of the COVID-19 storm: evidence-based decision making. Immun Ageing. 2021 May 20;18:24. |
dc.identifier.issn | 1742-4933 |
dc.identifier.uri | https://hdl.handle.net/11351/6797 |
dc.description | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Immunosenescence; Lockdown |
dc.description.abstract | Background
One hundred fifty million contagions, more than 3 million deaths and little more than 1 year of COVID-19 have changed our lives and our health management systems forever. Ageing is known to be one of the significant determinants for COVID-19 severity. Two main reasons underlie this: immunosenescence and age correlation with main COVID-19 comorbidities such as hypertension or dyslipidaemia. This study has two aims. The first is to obtain cut-off points for laboratory parameters that can help us in clinical decision-making. The second one is to analyse the effect of pandemic lockdown on epidemiological, clinical, and laboratory parameters concerning the severity of the COVID-19. For these purposes, 257 of SARSCoV2 inpatients during pandemic confinement were included in this study. Moreover, 584 case records from a previously analysed series, were compared with the present study data.
Results
Concerning the characteristics of lockdown series, mild cases accounted for 14.4, 54.1% were moderate and 31.5%, severe. There were 32.5% of home contagions, 26.3% community transmissions, 22.5% nursing home contagions, and 8.8% corresponding to frontline worker contagions regarding epidemiological features. Age > 60 and male sex are hereby confirmed as severity determinants. Equally, higher severity was significantly associated with higher IL6, CRP, ferritin, LDH, and leukocyte counts, and a lower percentage of lymphocyte, CD4 and CD8 count. Comparing this cohort with a previous 584-cases series, mild cases were less than those analysed in the first moment of the pandemic and dyslipidaemia became more frequent than before. IL-6, CRP and LDH values above 69 pg/mL, 97 mg/L and 328 U/L respectively, as well as a CD4 T-cell count below 535 cells/μL, were the best cut-offs predicting severity since these parameters offered reliable areas under the curve.
Conclusion
Age and sex together with selected laboratory parameters on admission can help us predict COVID-19 severity and, therefore, make clinical and resource management decisions. Demographic features associated with lockdown might affect the homogeneity of the data and the robustness of the results. |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | Immunity & Ageing;18 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | COVID-19 (Malaltia) - Epidemiologia |
dc.subject | Medicina clínica - Presa de decisions |
dc.subject | COVID-19 (Malaltia) - Factors de risc |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | /epidemiology |
dc.subject.mesh | Clinical Decision-Making |
dc.subject.mesh | Severity of Illness Index |
dc.title | The age again in the eye of the COVID-19 storm: evidence-based decision making |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s12979-021-00237-w |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | /epidemiología |
dc.subject.decs | toma de decisiones clínicas |
dc.subject.decs | índice de la gravedad de la enfermedad |
dc.relation.publishversion | https://doi.org/10.1186/s12979-021-00237-w |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Martín MC] Centro de Hemoterapia y Hemodonación de Castilla y León, Valladolid, Spain. [Jurado A, Yarce O, Navas AM] Department of Immunology and Allergology, Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), 14004 Córdoba, Spain. [Abad-Molina C, Orduña A] Department of Microbiology and Immunology, Hospital Clínico Universitario, Valladolid, Spain. [Hernández M, Perurena-Prieto J] Servei d’Immunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34016150 |
dc.identifier.wos | 000652608400001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |